Sarepta Therapeutics Inc (SRPT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sarepta Therapeutics Inc stock (SRPT) is currently trading at $17.61. Sarepta Therapeutics Inc PS ratio (Price-to-Sales) is 0.80. Analyst consensus price target for SRPT is $20.61. WallStSmart rates SRPT as Underperform.
- SRPT PE ratio analysis and historical PE chart
- SRPT PS ratio (Price-to-Sales) history and trend
- SRPT intrinsic value — DCF, Graham Number, EPV models
- SRPT stock price prediction 2025 2026 2027 2028 2029 2030
- SRPT fair value vs current price
- SRPT insider transactions and insider buying
- Is SRPT undervalued or overvalued?
- Sarepta Therapeutics Inc financial analysis — revenue, earnings, cash flow
- SRPT Piotroski F-Score and Altman Z-Score
- SRPT analyst price target and Smart Rating
Sarepta Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Sarepta Therapeutics Inc (SRPT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around peg ratio and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Sarepta Therapeutics Inc (SRPT) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 2664.00% year-over-year
90.17% of shares held by major funds and institutions
Trading at 1.54x book value, attractively priced
Supporting Valuation Data
Sarepta Therapeutics Inc (SRPT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -32.70%, a shrinking business
Company is losing money with a negative profit margin
Very expensive relative to growth, significant premium
Small-cap company with higher risk but more growth potential
Sarepta Therapeutics Inc (SRPT) Detailed Analysis Report
Overall Assessment
This company scores 46/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.5/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, EPS Growth, Institutional Own.. Valuation metrics including Price/Sales (0.80), Price/Book (1.54) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 2664.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including PEG Ratio (159.25) suggest expensive pricing. Growth concerns include Revenue Growth at -32.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -53.50%, Operating Margin at -92.60%, Profit Margin at -32.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -53.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -32.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SRPT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SRPT's Price-to-Sales ratio of 0.80x trades at a deep discount to its historical average of 470.24x (1th percentile). The current valuation is 100% below its historical high of 5135.65x set in Sep 2016, and 2% above its historical low of 0.78x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sarepta Therapeutics Inc (SRPT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Sarepta Therapeutics Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 2.2B with 33% decline year-over-year. The company is currently unprofitable, posting a -32.5% profit margin.
Key Findings
Generating 125M in free cash flow and 131M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 33% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -32.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Sarepta Therapeutics Inc.
Bottom Line
Sarepta Therapeutics Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sarepta Therapeutics Inc(SRPT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts.